Stella Pharma Reports Key Stakeholder Details; 33.66% Controlled by Stella Chemifa

TOKYO, Jun 24 (Pulse News Wire) – Stella Pharma Corporation (4888.T) disclosed key stakeholder information as of March 31, 2026. According to the report, Stella Chemifa holds 33.66% of the voting rights directly and indirectly.

Stella Pharma manufactures and sells boron drugs used in BNCT cancer treatments, such as Steboronin®. High-purity boron-10, essential for producing Steboronin's active ingredient Borofuran (10B), is sourced exclusively from Stella Kemifa Kabushiki Kaisha's technology. The company anticipates expanding this procurement relationship as its operations grow.

Despite this dependency, Stella Pharma maintains independent decision-making and operational independence as an independent public entity. In the fiscal year ending March 31, 2026, Stella Pharma reported a capital of 12,636 and transactions totaling 135,837 million yen with Stella Chemifa. The company adheres to fair pricing agreements based on manufacturing costs plus reasonable profit margins, ensuring minority shareholders' interests are protected through pre-approval by the audit committee and thorough board review.